Loading…
Loading…
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that the U.S. Food and Drug Administration (“FDA”) has completed its filing review and formally filed the Company's Premarket Approval (“PMA”) application for PMX, the Company's endotoxin removal therapy for patients with endotoxic septic shock (“ESS”). FDA acceptance for filing of the PMA application follows completion of the Agency's filing review process and confirms that the application contains all the information needed to proceed with the substantive review.
TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual and Special Meeting of shareholders (the "Shareholders") held on June 8, 2026 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 27, 2026 (the "Circular") to its Shareholders were approved.
Spectral Medical Inc. (EDT:CA) Shareholder/Analyst Call Transcript
100% follow-up achieved for all 157 patients enrolled in the Tigris trial Mortality at 12 months was 52.8% with PMX vs. 66.7% with standard of care alone (absolute risk reduction of 13.9%; number needed to treat of 7.2) 95.9% probability of benefit for PMX at 12 months, independent of prior clinical studies (Tigris data alone) Additional Bayesian and non-Bayesian analyses will be performed including incorporation of prior data from EUPHRATES TORONTO and DEERFIELD, Ill.
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for PMX, the Company's endotoxin removal therapy for patients with endotoxic septic shock (“ESS”).
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre. Dates: Tuesday April 21, 2026-Wednesday April 22, 2026 Time: 8:30 AM - 5:00 PM ET Location: Metro Toronto Convention Centre, North Building255 Front St WToronto, OntarioM5V 2W6 Chris Seto, CEO will be speaking at 1030 AM ET ON Wednesday, April 22nd.
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2025 and provided a corporate update.
No recent filings indexed.